Psychedelics - Spark Newswire

2 minute read

Filament Health Shares Q3 2022 Results, On Road To Becoming Industry’s Natural Psilocybin Supplier

Today, 4:14 PM

Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September 30, 2022.

FLHLF

2 minute read

Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial

By Lara Goldstein

Today, 4:14 PM

Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu

SILO

2 minute read

Atai Life Sciences’ Q3 2022 Financials & Business Update, ‘Strong Capability To Execute’

By Lara Goldstein

Today, 4:14 PM

Clinical-stage psychedelics company atai Life Sciences N.V. (NASDAQ: ATAI) reported its financial results for the quarter ended September 30, 2022 and shared business developments.

ATAI

3 minute read

Psychedelics Investment Holder Blackhawk Growth Hosts Meeting For Potential Subsidiary Spin-Out

By Lara Goldstein

Today, 4:14 PM

Blackhawk Growth Corp. (OTCMKTS: BLRZF), an investment holding company focused on acquiring and developing high-growth companies in the health, cannabis and psychedelics sectors in the US and Canada, announced it intends to complete a spin-out transaction of its wholly-owned subsidiaries MindBio Therapeutics Pty. Ltd.

BLRZF

5 minute read

Psyched: Brock Pierce Joins Psychedelic VC, Colorado’s Psychedelics Legalization, Zappy Zapolin’s Open Letter & More

By Lara Goldstein

Today, 4:14 PM

Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable'

ATAI

1 minute read

These Are The Top Companies And Most Influential People In The Psychedelics Space: Meet The Winners Of The Microdose Awards

By Javier Hasse

Today, 4:14 PM

Which are the top companies and who are the most influential people in the psychedelics space? According to Microdose Psychedelic Insights, host of the Microdose Awards, these are the ones to watch.

ATAI

4 minute read

EXCLUSIVE: Insider’s Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance

By Lara Goldstein

Today, 4:14 PM

(Part four of a four-part series) See previous stories in this series:

ATAI

2 minute read

Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial

By Lara Goldstein

Today, 4:14 PM

Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD).

BMNDF

2 minute read

COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term’s Highlights

By Lara Goldstein

Today, 4:14 PM

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.

CMPS